EGFR and cancer: The following crucial agenda should be considered: 1) implementation of EGFR genotyping for lung adenocarcinoma, 2) development of a distinct management paradigm for oncogene-addicted cancers, 3) better utilization of rebiopsy tissue for molecular studies of resistance, and 4) genotype-guided clinical trials of targeted therapies for patients with acquired TKI resistance [36].